Please ensure Javascript is enabled for purposes of website accessibility

Why Molecular Templates Stock Crashed Today

By Keith Speights - Apr 5, 2021 at 4:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is taking back rights to one drug candidate and discontinuing development of another.

What happened

Shares of Molecular Templates (MTEM 3.96%) closed down 23.6% on Monday. The big drop came after the company announced that it was resuming full rights of engineered toxin bodies (ETB) candidate TAK-169 from Takeda (TAK 1.77%). Molecular Templates also said that it's discontinuing the development of MT-3724, another experimental ETB.

So what

It's not surprising for a clinical-stage biotech stock to sink when a major partner pulls out on developing a drug. That's exactly what happened in this case.

Man wearing a coat and tie holding a red line trending down

Image source: Getty Images.

Takeda was evaluating TAK-169 in a phase 1 study for treating multiple myeloma. So why did the Japanese drugmaker back out? Molecular Templates CEO Eric Poma said that Takeda decided to "reprioritize its pipeline."

This move was directly related to Molecular Templates' own decision to throw in the towel on developing MT-3724. The U.S. Food and Drug Administration (FDA) placed the experimental drug on full clinical hold in late March after previously placing it on partial clinical hold following a treatment-related patient death. Molecular Templates concluded that its best chance of success was to refocus efforts on other therapies, including TAK-169 with the transfer of rights from Takeda.

Now what

Molecular Templates expects the transition of TAK-169 from Takeda will be completed over the next 90 days. The company plans to move forward with current phase 1 studies of TAK-169 and two other ETB candidates, MT-5111 and MT-6402. It anticipates that the assumption of full rights to TAK-169 will generate cost savings this year and won't impact its cash runway through the second half of 2023.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Molecular Templates, Inc. Stock Quote
Molecular Templates, Inc.
$1.05 (3.96%) $0.04
Takeda Pharmaceutical Company Limited Stock Quote
Takeda Pharmaceutical Company Limited
$14.98 (1.77%) $0.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.